(function(){var loadHandler=window['sl_{B169E353-1691-4AFC-B51D-F07AF60FC333}'];loadHandler&&loadHandler(4, '<div id="spr0_58785a07"><div id="spr1_58785a07" class="kern slide"><img id="img4_58785a07" src="data/img1.png" width="720px" height="540px" alt="" style="left:0px;top:0px;"/></div><div id="spr2_58785a07" class="kern slide"><img id="img0_58785a07" src="data/img3.png" width="721.48" height="100.8" alt="" style="left:-1.48px;"/><div id="svg1_58785a07" style="left:-1.48px;top:99.523px;"><svg width="722" height="4" viewBox="0 0 722 4"><path fill="#c76c02" d="M0,0 h721.48 v3.6 h-721.48 Z"/></svg></div><div id="svg2_58785a07" style="left:-1.48px;top:0.523px;"><svg width="722" height="4" viewBox="0 0 722 4"><path fill="#2e3546" d="M0,0 h721.48 v3.6 h-721.48 Z"/></svg></div><img id="img1_58785a07" src="data/img8.png" width="721.48" height="43.101" alt="" style="top:496.899px;"/><div id="spr3_58785a07" style="left:657.715px;top:499.855px;"><img id="img2_58785a07" src="data/img9.png" width="56" height="36" alt="CHRC logo_with text.psd" style="left:-0.105px;top:-0.177px;"/></div><div id="spr4_58785a07" style="left:0px;top:7.56px;"><div style="width:0px;"><span id="txt0_58785a07" data-width="355.957031" style="left:182.87px;top:5.272px;">FOURIER Outcomes Trial</span></div><div style="width:0px;"><span id="txt1_58785a07" data-width="166.698135" style="left:282px;top:48.171px;">Evolocumab</span></div></div><div id="spr5_58785a07" style="left:6.496px;top:508.59px;"><div style="width:0px;"><span id="txt2_58785a07" class="nokern" data-width="180.953613" style="left:7.2px;top:4.096px;">Sebatine MS, et al. N Engl J Med. 2017;376:1713-1722</span></div></div><div id="spr6_58785a07" style="left:11.919px;top:146.662px;"><img id="img3_58785a07" src="data/img11.png" width="696" height="228" alt="" style="left:0.081px;top:-0.151px;"/></div><div id="spr7_58785a07" style="left:11.919px;top:386.051px;"><div style="width:0px;"><span id="txt3_58785a07" class="nokern relpos" style="left:7.2px;top:5.043px;"></span><span id="txt4_58785a07" class="relpos" data-width="192.752930" style="left:21.465px;top:4.436px;">Primary Efficacy Endpoint: </span><span id="txt5_58785a07" class="relpos" data-width="420.741211" style="left:21.46px;top:4.436px;">composite of CV death, MI, stroke, hospitalization for UA, or</span></div><div style="width:0px;"><span id="txt6_58785a07" data-width="187.866211" style="left:29.7px;top:26.036px;">coronary revascularization</span></div><div style="width:0px;"><span id="txt7_58785a07" class="nokern relpos" style="left:7.2px;top:48.243px;"></span><span id="txt8_58785a07" class="relpos" data-width="213.257813" style="left:21.465px;top:47.636px;">Secondary Efficacy Endpoint: </span><span id="txt9_58785a07" class="relpos" data-width="237.041016" style="left:21.46px;top:47.636px;">composite of CV death, MI, stroke</span></div></div></div></div>');})();